Kirk Ways's most recent trade in Spruce Biosciences Inc was a trade of 5,000 Restricted Stock Units done . Disclosure was reported to the exchange on Dec. 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Spruce Biosciences Inc | Kirk Ways | Director, Interim Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 5,000 | 5,000 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Kirk Ways | Director, Interim Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2025 | 1,250 | 3,750 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Kirk Ways | Director, Interim Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2025 | 1,250 | 1,250 | - | 0 | Common Stock | |
| Spruce Biosciences Inc | Kirk Ways | Director, Interim Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 400 | 400 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Kirk Ways | Director, Interim Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Dec 2025 | 400 | 0 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Kirk Ways | Director, Interim Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 266 | 266 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Kirk Ways | Director, Interim Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Dec 2025 | 266 | 0 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Kirk Ways | Director, Interim Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Kirk Ways | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Kirk Ways | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Kirk Ways | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 20,625 | 20,625 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Kirk Ways | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) |